Search

Displaying results 2271 - 2280 of 10000 in total
  1. Drug

    Sarilumab

    go.drugbank.com/drugs/DB11767
    ApprovedInvestigational

    [A27262] Sarilumab was developed by Sanofi and Regeneron Pharmaceuticals, Inc; it was US FDA-approved in May 2017 and followed by EU approval in June 2017 for the treatment of moderate to severe rheumatoid … cascades of IL-6.

    Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 Inducers
  2. Drug

    Chloramphenicol succinate

    go.drugbank.com/drugs/DB07565
    Approved

    [L14174] Chloramphenicol succinate was granted FDA approval on 20 February 1959.[L12711] … [A192987] Chloramphenicol is a bacteriostatic antibiotic.[A204065] Use of chloramphenicol succinate and chloramphenicol has decreased due to the risk of potentially fatal blood dyscrasias.

    Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, P-glycoprotein substratesProducts: SUMICLORAN ® 1 G INYECTABLE, GEMYSETIN SÜKSİNAT 1G I.M./ I.V. ENJEKSİYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN LİYOFİLİZE TOZ, 100 FLAKON
  3. Drug

    Propyphenazone

    go.drugbank.com/drugs/DB13524
    Investigational

    Propyphenazone is a non-steroidal anti-inflammatory agent with analgesic effects.[A275063, A275068]

    Mixtures: DERMAN 300 MG/100 MG/50 MG KAŞE, 1 KAŞE, Adolomed 250 mg/300 mg/50 mg TablettenCategories: Non COX-2 selective NSAIDS, Heterocyclic Compounds, 1-Ring
  4. Drug

    Ferrous bisglycinate

    go.drugbank.com/drugs/DB11210
    Approved

    Ferrous bisglycinate is a chelate that is used as a source of dietary iron. … Forming a ring structure when reacting with glycine, ferrous bisglycinate acts as both a chelate and a nutritionally functional [A27250].

    Mixtures: Folika-MG, PNV Tabs 20-1
  5. Drug

    IGN101

    go.drugbank.com/drugs/DB06500
    Experimental

    It consists of 500 ug 17-1A antibody adsorbed on aluminum hydroxide.

  6. Drug

    Chymotrypsin

    go.drugbank.com/drugs/DB09375
    ApprovedInvestigationalVet approvedWithdrawn

    Chymotrypsin (EC 3.4.21.1) is a digestive enzyme that promotes proteolysis, or the breakdown of proteins and polypeptides. … Chymotrypsin is the most abundant pancreatic proteases that represent up to 10-20% of the total protein synthesized by the exocrine pancreas [A32637].

    Synonyms: Chymotrypsin A, Chymotrypsin B
  7. Drug

    Phenylpropanolamine

    go.drugbank.com/drugs/DB00397
    ApprovedVet approvedWithdrawn

    Phenylpropanolamine is a sympathomimetic agent that acts as a nonselective adrenergic receptor agonist and norepinephrine reuptake inhibitor. … It has been used as a decongestant and appetite suppressant. Currently, it is withdrawn from the market in Canada and the United States due to the risk for hemorrahgic strokes.

    Mixtures: PAROL COLD 325 MG KAPSUL, 20 ADET, GLİFENTOL ŞURUP, 150 MLCategories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates, Adrenergic beta-2 Receptor Agonists
  8. Drug

    Revefenacin

    go.drugbank.com/drugs/DB11855
    ApprovedInvestigational

    [A40026] It was developed by Theravance Biopharma and FDA approved on November 9, 2018.[L4818] … The LAMA group falls into a parent category known as long-acting inhaled bronchodilators and this type of agents are recommended as a maintenance therapy for chronic obstructive pulmonary disease (COPD

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 Substrates
  9. Pathway

    Metabolism and Physiological Effects of Creatinine

    smpdb.ca/view/SMP0123283
    Metabolic

    Creatinine is a low-molecular-weight uremic solute and breakdown product of creatine phosphate in muscle, often used as a clinical marker of renal function (altered serum creatinine clearance levels can indicate pathophysiology in variou...

    Drugs: Ademetionine · Arginine · Ornithine · Glycine · Creatine · Glycocyamine
    Enzymes: Y+L amino acid transporter 2
  10. Drug

    Naloxegol

    go.drugbank.com/drugs/DB09049
    ApprovedInvestigational

    Naloxegol, for "PEGylated naloxol" is a peripherally-selective opioid antagonist developed by AstraZeneca. … It was approved by the FDA in September 2014 and is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non‑cancer pain.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 InhibitorsSynonyms: (5α,6α)-17-Allyl-6-[(20-hydroxy-3,6,9,12,15,18-hexaoxaicos-1-yl)oxy]-4,5-epoxymorphinan-3,14-diol